Skip to main content

Advertisement

Fig. 1 | BMC Infectious Diseases

Fig. 1

From: Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study

Fig. 1

Study designs for (a) the Phase 2/3 group and (b) the Phase 1 group. a As part of a response-guided treatment duration, all HCV therapy was stopped at Week 24 in patients who achieved HCV RNA levels <25 IU/ml (detectable or undetectable) at Week 4, and <25 IU/ml undetectable HCV RNA levels at Week 12. For patients who did not achieve these criteria, PegIFNα-2a and RBV treatment continued until Week 48. PegIFNα-2a/RBV peginterferon α-2a with ribavirin, QD once daily, RGT response-guided therapy, SMV simeprevir

Back to article page